Effect of Ropeginterferon Alfa-2b in Prefibrotic Primary Myelofibrosis

In conclusion, the data demonstrate that Ropeginterferon-alfa-2b is able not only to induce hematologic responses but also to improve constitutional symptoms and overall quality of life in prefibrotic PMF. Thus ropeginterferon-alfa-2b warrant further investigation as a treatment option in prefibrotic PMF, where only very limited alternatives exist.DisclosuresGisslinger: Shire: Consultancy, Honoraria; Janssen Cilag: Consultancy, Honoraria; Novartis: Honoraria, Research Funding; AOP Orphan Pharmaceuticals AG: Consultancy, Honoraria, Research Funding. Krejcy: AOP Orphan Pharmaceuticals: Employment. Widmann: AOP Orphan Pharmaceuticals: Employment. Kralovics: MyeloPro Diagnostics and Research GmbH: Equity Ownership. Krauth: Novartis: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Celgene: Consultancy, Honoraria.

Source: Blood - November 21, 2018 Category: Hematology Authors: Gisslinger, H., Gisslinger, B., Schalling, M., Krejcy, K., Widmann, R. S., Kralovics, R., Krauth, M.-T. Tags: 634. Myeloproliferative Syndromes: Clinical: Poster II Source Type: research